On April 6, 2026 Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, reported that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, CA, from April 17 – 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR (Free AACR Whitepaper) presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics," said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.

"The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR (Free AACR Whitepaper). It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026," said Scott Hutton, CEO, Biodesix.

Tumor & Immune Profiling Expertise

Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR, and Thermo Fisher Ion AmpliSeq platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent Genexus System. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.

Sunday, April 19 | 3PM–5PM PST​ | Oral Presentation | Room 17, Mezzanine Level, Convention Center
​Title: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations​

Monday, April 20 | 2PM–5PM PST | Poster Section 41
Poster: 3743. ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR (ddPCR) panel for ultra-sensitive NSCLC biomarker detection

Wednesday, April 22 | 9AM–12PM PST​ | Poster Section 39​
Poster: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer​

Monday, April 20 | 2PM–5PM PST​ | Poster Section 44​
Title: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system​

Molecular Residual Disease (MRD) Product Pipeline

Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.

Monday, April 20 | 12:30PM | Spotlight Theater B – Sails Pavilion – Conv Ctr
Title: Leveraging Droplet Digital PCR* (ddPCR) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies

Tuesday, April 21 | 2PM–5PM PST​ | Poster Section 1​
Poster: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.​

​Wednesday, April 22 | 9AM–12PM PST​ | Poster Section 45​
Poster: 7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs​

The full abstracts for Biodesix and a list of all abstracts being presented at the AACR (Free AACR Whitepaper) Annual Meeting can be found here.

ddPCR technology is a trademark of Bio-Rad Laboratories, Inc.
Ion Torrent Genexus System and Ion AmpliSeq Platform are trademarks of Thermo Fisher Scientific.
NSCLC is the acronym for Non-Small Cell Lung Cancer.

(Press release, Biodesix, APR 6, 2026, View Source [SID1234664192])

On April 6, 2026 Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) reported that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds ("MFW") at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place on April 17-22, 2026, in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Venkat Nelabhotla, CEO of Vyome, stated that, "There are currently no FDA approved drugs to treat malodor and other symptoms of MFW. We plan to have FDA interactions in Q2 2026 on the pivotal study design. Recent third-party analysts estimated the total addressable U.S. market to be approximately USD 2.2 billion. Inflammation is one of the biggest healthcare problems facing the world today."

The research will be presented at the session "Phase II and Phase III Clinical Trials in Progress." Vyome will highlight mechanistic insights together with detailed clinical data comparing the VT-1953 active treatment with vehicle treatment in a Phase 2 study. VT-1953 is a first-in-class treatment for malodor and other symptoms of MFW in advanced cancer patients, which acts by a dual mechanism of action, inhibiting DNA Gyr and modulating MD2/TLR interactions, an inflammatory signal. MFW is a rare, debilitating condition that occurs in ~10% of advanced cancer patients, severely impacting the quality of life.

"We are delighted that AACR (Free AACR Whitepaper) found our data compelling for presentation at the annual meeting. Based on our promising clinical data underpinned by strong mechanistic alignment, we are advancing VT-1953 into pivotal studies," said Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School, Co-founder and Board member of Vyome.

The details of the presentation at the 2026 AACR (Free AACR Whitepaper) Annual Meeting are:

American Association for Cancer Research Annual Meeting 2026, San Diego

Date: April 21, 2026, 9:00 AM – 12:00 PM

Session title: (PO.CTP01.03) Phase II and Phase III Clinical Trials in Progress

Presentation number and title: CT208 / 3 – Final results from a phase 2 trial testing safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wound

Authors: Arshit Narang, MBBS, Prashant Prakash Lad, MD, Shiladitya Sengupta PhD

(Press release, Vyome Therapeutics, APR 6, 2026, View Source [SID1234664191])

On April 6, 2026 ABION (KOSDAQ, 203400), a precision oncology therapeutics developer, reported that its next-generation immuno-oncology candidate, ABN202, demonstrated a superior anti-cancer mechanism compared with TROP2-targeting antibody-drug conjugates (ADCs) in preclinical studies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The findings will be presented as a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2026), to be held April 17–22 in San Diego, USA.

ABN202 is a next-generation immuno-oncology drug candidate based on the company’s proprietary iRAC (Interferon-β Antibody Conjugate) platform, designed to enable both direct tumor cell killing and robust immune activation. In the study, ABN202 demonstrated a superior anti-cancer mechanism compared with currently approved TROP2-targeting ADCs.

Notably, ABN202 overcame resistance to TROP2-targeting ADCs and showed superior anti-tumor efficacy compared with ADCs combined with anti-PD-1 immune checkpoint inhibitors in preclinical models. In addition, ABN202 induced sustained and systemic CD8-positive T cell-mediated immune responses, suggesting the potential for durable anti-tumor immunity.

These findings suggest that ABN202 represents a novel immuno-oncology strategy capable of overcoming resistance associated with existing ADC therapies, highlighting its strong potential as a new treatment option for patients with solid tumors who have failed prior ADC-based therapies.

ABION’s first-in-class iRAC platform can be applied not only to TROP2-targeting antibodies but also to a broad range of solid tumor targets. This platform’s versatility positions iRAC as a promising next-generation immuno-oncology approach with potential pipeline expansion opportunities.

Dr. Young Kee Shin, CEO/CTO of ABION, said, "These results highlight the potential of a differentiated IFN-β-based immuno-oncology strategy to overcome resistance to current ADC therapies. Based on these encouraging preclinical findings, we are also actively exploring strategic partnership opportunities for ABN202, including collaborations at the preclinical stage."

(Press release, ABION, APR 6, 2026, View Source;Antibody-Fusion-ABN202-Outperforms-TROP2-Targeting-ADCs [SID1234664190])

On April 6, 2026 Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), reported an upcoming presentation of non-clinical data for K‑679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa’s proprietary micelle technology, has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 to be held in San Diego, California, from April 17 to 22, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details
Presentation Title: Selective intratumoral distribution and post-T-DXd activity of K-679, an ultra-high-DAR EGFR-targeted antibody drug-loaded unimicelle conjugate (ADUC)
Session Title: Antibody Technologies and Platforms 2
Presentation Date and Time: April 21, 2026, 9:00 a.m. – 12:00 p.m. CST (10:00 a.m. – 1:00 p.m. ET)
Poster Number: 4396
Presenter: Hideo Yoshida

The abstract of the presentation is available at
AACR Annual Meeting 2026 Itinerary Planner | Presentation

More information about the AACR (Free AACR Whitepaper) Annual Meeting 2026 can be found on the event website at the following link: AACR (Free AACR Whitepaper) Annual Meeting 2026 | Meetings | AACR (Free AACR Whitepaper)

About K-679
K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using Kowa’s proprietary micelle technology, currently in nonclinical development. The conjugate combines an anti-EGFR antibody with drug (DM1)-loaded unimicelles, which incorporate substantial quantities of payloads into a single-chain polymer. This innovative approach achieves an ultra-high DAR (Drug-to-Antibody Ratio) of approximately 45 DM1 molecules per antibody, significantly higher than conventional ADCs.

In non-clinical studies, K-679 has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and concordant spatial pharmacodynamic effects in xenograft models, compared with a benchmark antibody-drug conjugate (ADC). K-679 also showed anti-tumor activity in colorectal patient-derived xenograft (PDX) models with low and heterogeneous epidermal growth factor receptor (EGFR) expression.

(Press release, Kowa, APR 6, 2026, View Source [SID1234664189])

On April 6, 2026 DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage whole-genome cell-free DNA (cfDNA) assays for cancer detection and monitoring, reported it will present five poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2026 Annual Meeting, taking place April 17–22, 2026 in San Diego, CA. The presentations highlight advances across DELFI’s platform, including lung cancer subtyping, immunotherapy response prediction, the clinical utility of ctDNA-based molecular response, treatment monitoring on ultra high-throughput, next-generation sequencing platforms, and colorectal cancer treatment response monitoring.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s AACR (Free AACR Whitepaper) presentations reflect the breadth and maturity of our AI-driven, computational platform," said Susan Tousi, CEO. "From early detection to treatment monitoring, we’re generating clinical evidence across the cancer continuum that reinforces the power of genome-wide cfDNA analysis combined with AI. These five abstracts represent meaningful contributions from our team and our academic collaborators at Johns Hopkins and the Netherlands Cancer Institute."

Poster Presentations at AACR (Free AACR Whitepaper) 2026

Sunday, April 19 | 2:00–5:00 PM PT
Cell-Free DNA Fragmentome Profiles Predict Immunotherapy Response

Session: Liquid Biopsies: Circulating Nucleic Acids 1
Poster Section 44, Board 15 | Abstract #1134
Presenter: Valsamo Anagnostou, MD, PhD, Johns Hopkins University
Lung Cancer Subtyping Using Cell-Free DNA Fragmentomes and Protein Biomarkers

Session: Liquid Biopsies: Circulating Nucleic Acids 1
Poster Section 44, Board 16 | Abstract #1135
Presenter: Laurel Millberg, MSc, DELFI Diagnostics
Clinical Utility of Landmark ctDNA Molecular Response as an Early Indicator of Immunotherapy Outcomes in Lung Cancer

Session: Liquid Biopsy: Multi-Analyte and Multi-Omic
Poster Section 5, Board 17 | Abstract #110
Presenter: Jaime Wehr, MS, Johns Hopkins University
Monday, April 20 | 2:00–5:00 PM PT
Enhanced cfDNA Fragmentation-Based Treatment Monitoring on the Ultima Genomics Platform

Session: Liquid Biopsies: Circulating Nucleic Acids 3
Poster Section 45, Board 24 | Abstract #3863
Presenter: Laurel Millberg, MSc, DELFI Diagnostics
Tuesday, April 21 | 9:00 AM–12:00 PM PT
Cell-Free DNA Fragmentomes for Treatment Response Monitoring in Patients with Metastatic Colorectal Cancer: The DOLPHIN Study

Session: Liquid Biopsies: Circulating Nucleic Acids 4
Poster Section 45, Board 20 | Abstract #5325
Presenter: Denise van Steijn, MSc, Netherlands Cancer Institute
The five presentations reflect the expanding clinical evidence base for DELFI’s technology platform, which uses AI and machine learning to analyze genome-wide patterns of cell-free DNA fragmentation in blood. The research spans early detection, cancer subtyping, immunotherapy response prediction, and treatment monitoring across multiple cancer types and sequencing platforms.

In early detection, DELFI has clinically validated FirstLook Lung, a blood-based test designed to improve early detection of lung cancer, the leading cause of cancer death in the United States. New data being presented at AACR (Free AACR Whitepaper) 2026 extend the platform’s capabilities into lung cancer subtyping and immunotherapy response prediction, demonstrating how fragmentation patterns and protein biomarkers can provide clinical insights beyond initial detection.

On the treatment-monitoring front, DELFI-TF*, the company’s tumor-fraction-based monitoring solution, continues to generate clinical validation data across cancer types. The DOLPHIN study presentation describes a multicenter, prospective, observational study from the Netherlands Cancer Institute that examines new potential applications for cfDNA-based treatment response monitoring in ~500 colorectal cancer patients treated with systemic chemotherapy.

Additionally, new DELFI-TF data generated on the Ultima Genomics platform underscore the adaptability of DELFI’s core genomics technology and identify promising avenues for performance enhancement in future product generations.

"We are excited to present our latest work in early detection, treatment monitoring, subtyping, and technology innovation, " said Amoolya Singh, PhD, Chief Technology Officer. "We continue to believe that the sensitivity, low cost, and versatility of our technical approach position us well for continued scientific discovery and product development."

(Press release, Delfi Diagnostics, APR 6, 2026, View Source [SID1234664188])